Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009




Bortezomib Relapsed vs.
       Refractory               Median PFS*             Median OS**
-----------------------         -----------             -----------

                                                     Not Reached at 38+
Bortezomib Relapsed (n=20)       8.8 months                months
--------------------------       ----------          ------------------
                              95% CI (6.3, 11.2)      95% CI (25, NR)
                              ------------------      ---------------


Bortezomib Refractory (n=53)     5.7 months             22.5 months
                                 ----------             -----------
                              95% CI (4.3, 6.4)       95% CI (12.3, NR)
----------------------------  -----------------       -----------------


*  Median PFS and median TTP were identical, as no patient deaths
   occurred prior to progression.
** Kaplan Meier methodology was used to determine overall survival
   figures.

No unexpected adverse events have been observed. Toxicities were manageable with supportive care.

Commenting on the data, Dr. Paul Richardson stated, "Perifosine continues to demonstrate an impressive response rate and extended progression-free survival when combined with bortezomib and dexamethasone in a heavily pre-treated patient population. The new survival data reported is particularly encouraging with a median overall survival of more than 2 years. We look forward to pursuing this combination in the randomized Phase 3 trial."

Dr. Kenneth Anderson, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, added, "The data presented here further supports the planned Phase 3 trial design which has been granted Special Protocol Assessment by the FDA. We are excited to be launching the multi-center trial for this very promising agent."

Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We wish to thank the im
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. ... that once-daily naldemedine met its primary and secondary endpoints ... treatment of opioid-induced constipation (OIC) in adult patients with ... acting mu-opioid receptor antagonist (PAMORA). This is the third ... and key secondary endpoints. Study results showed ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Orbitz Worldwide, Inc. (NYSE: OWW ) will host a conference call to ... on Wednesday, May 5, 2010 at 10:00 a.m. EDT ( 9:00 ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20070813/AQM125LOGO ) , ... A live webcast of the call can be accessed through the Orbitz Worldwide ...
... April 26 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced ... will present at Deutsche Bank,s 35th Annual Health Care Conference on Monday, ... InterContinental Boston Hotel in Boston, MA. , ... A live webcast of the presentation may be accessed from the ...
Cached Medicine Technology:Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 2Orbitz Worldwide, Inc. to Host First Quarter 2010 Earnings Call on May 5 3
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years of marital bliss ... on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas lead the non-denominational ... the ceremony was a reception, with music by the Moonlight Serenade Orchestra and a ...
(Date:8/4/2015)... ... 2015 , ... Centurion Service Group, the world's largest medical equipment auction house, ... , The live auction will take place on Thursday, August 6 beginning ... at 5025 North Hiatus Road Sunrise, FL 33351. Anyone can participate in the auction ...
(Date:8/4/2015)... ... August 04, 2015 , ... Dr. Gary Richter, ... America’s Favorite Veterinarian. The contest is put on by the American Veterinary Medical ... nominees. Nominees were evaluated on community involvement, ethical behavior, passion for profession, and ...
(Date:8/4/2015)... ... August 04, 2015 , ... The goal of looking ... the desire for invasive surgery to achieve this ideal is not. But minimally invasive ... crave without the high cost or lengthy recovery time, according to Valerie Goldburt, ...
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of Ben C. ... claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter ... Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3
... , , ... ViroPharma Incorporated (Nasdaq: VPHM ... Committee supports the FDA,s Office of Generic Drugs (OGD) draft guidelines ... used to treat severe, often life-threatening bacterial infections of the gastrointestinal ...
... , , ALISO VIEJO, Calif., Aug. ... ), a premier anatomic pathology and molecular testing services resource for pathologists, ... quarter and six months ended June 30, 2009. Financial results included ... versus the second quarter of 2008, and a 43 percent increase in ...
... 4 /PRNewswire-FirstCall/ - Covidien (NYSE: COV ), a ... Inc. (TSX:NRI), a Canadian drug development company, today announced ... set a new action date under the Prescription Drug ... solution 1.5% w/w of November 4, 2009. , During ...
... delivery was vaginal or C-section doesn,t matter, study finds ... anesthesia during a Cesarean delivery doesn,t increase the risk ... , "We found that the incidence of learning disabilities ... those who were delivered via C-section but with general ...
... 5 years after the attacks, but asthma rates have steadily ... People directly exposed to the horrors of the Sept. 11, ... City were reporting new symptoms of post-traumatic stress as long ... study has found. , In fact, by 2006-2007, more people ...
... Petition drive by National Center ... captures 1 million signatures , , WASHINGTON, Aug. 4 ... today the 1 millionth signature on their joint "Free Our Health Care ... health care system. , , The millionth signature milestone comes ...
Cached Medicine News:Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 2Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 3Health News:ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 2Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 3Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 4Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 5Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 6Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 7Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 8Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 9Health News:Clarient Reports Second Quarter Revenue Up 40 Percent 10Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 2Health News:FDA extends review of Pennsaid(R) diclofenac sodium topical solution 3Health News:No Link Found Between Birth Anesthesia and Learning Issues 2Health News:For Many, 9/11-Linked Trauma Emerged Years Later 2Health News:For Many, 9/11-Linked Trauma Emerged Years Later 3Health News:One Million Americans - and Counting - Come Out Against President Obama's Health Care Plan 2Health News:One Million Americans - and Counting - Come Out Against President Obama's Health Care Plan 3
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: